达洛鲁胺

Description

Darolutamide · CAS 1297538-32-9 · C19H19ClN6O2. UNII X05U0N2RCO. Boiling Point: 719.5±60.0; LogP: 1.904; Dissociation Constants: 11.75.

Identification

CAS Registry Number	1297538-32-9
PubChem CID	67171867
Molecular formula	C19H19ClN6O2
IUPAC name	N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
UNII (FDA)	X05U0N2RCO

Computed Descriptors

Molecular Weight	398.8
XLogP3	1.8
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	6
Exact Mass	398.1258016
Monoisotopic Mass	398.1258016
Topological Polar Surface Area	120
Heavy Atom Count	28
Formal Charge	0

Physical & Chemical Properties

Boiling Point	719.5±60.0
LogP	1.904
Dissociation Constants	11.75

Physical description & handling notes

• Darolutamide, through its downstream effects on cancer cell growth, treats castrate-resistant prostate cancer. It inhibits cancer cell growth and markedly lowers prostate specific antigen (PSA) levels through potent androgen receptor antagonism.

GHS Hazard Classification

Reported hazard statements	H302 (100%), H400 (100%), H410 (100%)

Documented Uses

• Darolutamide is indicated for the treatment of adults with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), either as monotherapy or in combination with docetaxel.
• Darolutamide is a third generation, oral nonsteroidal antiandrogen used to treat nonmetastatic castration-resistant prostate cancer. Darolutamide is associated with a low rate of serum enzyme elevation during therapy, but has not been linked to cases of clinically apparent liver injury with jaundice.
• Darolutamide is approved to treat:
• • Prostate cancer. It is used in adults whose cancer:
• • Has spread to other parts of the body and responds to treatment that lowers testosterone levels. It is used alone or with docetaxel.
• • Has not spread to other parts of the body and no longer responds to treatment that lowers testosterone levels.

Synonyms

Darolutamide; 1297538-32-9; ODM-201; Nubeqa; BAY1841788; BAY-1841788; darolutamida; X05U0N2RCO; BAY 1841788; N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; DTXSID101027953; darolutamidum; N-((2S)-1-(3-(3-chloro-4-cyanophenyl)pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Antiandrogen ODM-201; RefChem:58141; L02BB06

Frequently Asked Questions

What are the CAS number and molecular formula of Darolutamide?

CAS 1297538-32-9; molecular formula C19H19ClN6O2; molecular weight — g/mol.

What other names is Darolutamide known by?

Darolutamide, 1297538-32-9, ODM-201, Nubeqa, BAY1841788, BAY-1841788.

Is Darolutamide classified as hazardous?

Hazard statements reported: H302, H400, H410.

What are the key physical properties of Darolutamide?

Boiling Point: 719.5±60.0; LogP: 1.904; Dissociation Constants: 11.75.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.